Lymphoma

Researchers are testing whether combining two chemotherapy drugs, pralatrexate and romidepsin, is safe and effective for people with lymphoid cancers that have returned or stopped responding to treatment. The trial first finds the highest dose people can tolerate, then gives that…

This study tests a new treatment called 4SCAR-CD44v6 T cells for people with cancers that have a specific protein called CD44v6. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The trial will enroll 100 participants to check sa…

This study tests the safety and best dose of loncastuximab tesirine, a targeted antibody-drug conjugate, in people with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma who also have moderate or severe liver impairment. The goal is to find a dosi…

This early-stage study tested a new drug called ONO-7018 in 9 adults with non-Hodgkin lymphoma or chronic lymphocytic leukemia that had returned or stopped responding to other treatments. The main goal was to find a safe dose and check for side effects. The study was stopped earl…

This study tested a reduced-intensity bone marrow transplant, or 'mini transplant,' for people with blood cancers like lymphoma and leukemia. The transplant used marrow from a relative and was combined with chemotherapy drugs to help the donor cells take hold. Only 15 people took…

This study tested two experimental drugs, maplirpacept and glofitamab, given after a single dose of obinutuzumab, in adults with diffuse large B-cell lymphoma (DLBCL) that had returned or not responded to prior treatments. Participants had already tried at least two standard ther…

This early-phase study tested the safety of a drug called tazemetostat in people with a type of blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to other treatments. Only 6 participants were enrolled before the study was stopped early. The go…

This study tested whether adding the targeted drug inotuzumab ozogamicin before and after a stem cell transplant could help control leukemia and lymphoma. It included 15 people aged 12 to 75 with certain blood cancers. The study was stopped early, but researchers looked at safety…

This study tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) after a stem cell transplant could safely help control high-risk multiple myeloma and lymphoma. It involved 46 adults aged 18-80 whose cancer was at high risk of coming back. The main goal was to …

This early-stage trial tested a combination of two immune-boosting drugs—pembrolizumab (Keytruda) and CMP-001—in 14 adults with lymphomas that had come back or stopped responding to treatment. The goal was to find a safe dose that could shrink tumors. However, the study was termi…

This study tested whether adding an extra drug (ALLO-647) to standard chemotherapy before a special immune cell treatment (CAR T) could help adults with a hard-to-treat type of lymphoma. Only 2 people joined before the trial was stopped early. The goal was to see if the new combi…

This phase 2 study tested umbralisib (a PI3K blocker) plus rituximab (an antibody that targets B-cells) as the first treatment for people with follicular or marginal zone lymphoma. The goal was to see how many patients had their tumors disappear completely. Only 18 people enrolle…

This early-phase trial tested the drug ASTX660 in just 8 people with T-cell lymphoma that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for side effects, but it was stopped early. Because it was so small and incomplete, we cannot…

This study tested the drug pembrolizumab in people with a hard-to-treat type of lymphoma (DLBCL) that has certain genetic changes in the PD-L1 gene. The goal was to see if the drug could shrink tumors. However, the study was stopped early after enrolling only 5 participants, so t…

This early-stage trial tested an oral drug called HMPL-523 in 69 people with lymphoma that had returned or stopped responding to other treatments. The main goals were to check safety and find the right dose. The study was terminated early, so we have limited information on how we…

This study tested a new treatment called CTX110 for people with B-cell blood cancers that came back or didn't respond to standard therapy. CTX110 uses donor immune cells that are edited with CRISPR technology to target and attack cancer cells. The trial enrolled 93 adults and aim…

This early-phase study tested a new treatment called bbT369 for people with a type of blood cancer (B cell non-Hodgkin's lymphoma) that had come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified to better recognize a…

This study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…

This study tested the drug ofatumumab (Arzerra) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who still had signs of disease after chemotherapy. The goal was to see if the drug could clear remaining cancer cells and keep the disease under c…

This pilot study looked at whether radiation therapy could help people with lymphoma that did not respond to CAR T cell therapy. Only 3 participants were enrolled before the study was terminated. The main goal was to check safety and side effects of adding radiation shortly after…

This early-stage trial tested two drugs, isatuximab and cemiplimab, together in 58 people with relapsed or refractory lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study was terminated early, so while some safety and response data were col…

This early-stage trial tested an experimental drug called SAR441000, injected directly into tumors, either alone or with another drug (cemiplimab) given through a vein. The study aimed to find a safe dose and see if the combination could shrink tumors in people with advanced soli…

This early-phase trial tested a combination of three drugs—maplirpacept, tafasitamab, and lenalidomide—in 6 people with diffuse large B-cell lymphoma (DLBCL) that had returned or not responded to prior treatment. Participants could not have a stem cell transplant or CAR-T therapy…

This study looks at whether a special ECG and a blood test can find early signs of heart weakness in adult cancer survivors who had certain chemotherapy. Researchers will check how well these tests work compared to standard heart imaging. The goal is to gather information needed …

This study tested a smartphone app called HeartPhone that appears on the lock screen to encourage physical activity in breast cancer, leukemia, and lymphoma survivors. Participants used the app for 3 months and wore a Fitbit to track activity. The goal was to see if the app could…

This study tested a sensory rehabilitation program for people who lost their sense of smell or taste after chemotherapy for blood cancers like multiple myeloma or lymphoma. The program involved exercises to retrain the nose and tongue. Only 5 people enrolled before the study ende…

This study examines the medical records of 400 people diagnosed with various types of lymphoma at a French hospital between 1999 and 2018. Researchers want to see how long patients survived and whether the care they received matched what medical guidelines recommend. The goal is …

This study tested a method that uses real-time imaging to guide a minimally invasive surgical tool for taking lymph node samples from the abdomen. The goal was to see if this approach could make the biopsy more accurate and reduce risks compared to standard surgery. The study inc…

This observational registry aims to learn about the health, wellbeing, and needs of people who were diagnosed with cancer between ages 18 and 39. Participants complete surveys every 6 to 12 months about anxiety, depression, social support, and financial distress. The registry als…